Would you like to participate in a clinical research study for narcolepsy?

We are inviting you to take part in a clinical research study for adults with narcolepsy. The study drug will be given at no cost to you, and you will not be charged for any study doctor visits, laboratory work, tests, or procedures that are needed for the study. In addition, you will be reimbursed after each completed study visit. No health insurance is required.

The Narcolepsy Clinical Study is evaluating an investigational drug (also known as the “study drug”) called SUVN-G3031 as a possible treatment for narcolepsy with cataplexy or narcolepsy without cataplexy, a sleep disorder that causes daytime drowsiness with or without muscle weakness.

To be eligible for this study, you must be:

  • 18 to 50 years of age
  • Diagnosed with narcolepsy with or without cataplexy
  • Interested in participating in a narcolepsy clinical research study
As a study participant, all study-related care will be provided at no cost to you and you will be reimbursed after each completed study visit.
Participate
Participate
Participate

Sign Up

What happens if I sign up? We will match you to a study site in your area that needs adults with narcolepsy or notify you when one becomes available. The study team will then contact you and you may have the opportunity to participate if qualified.


If you think you might like to participate in the Narcolepsy Clinical Study or would like more information, please enter your information below so we can see if you may qualify and can contact you about the study. Keep in mind that participation is entirely voluntary. If you do decide to take part in a study, you may change your mind about participating at any time.

About Narcolepsy

Narcolepsy is a long-term neurological disorder that specifically affects the regulation of sleep-wake cycles. The disorder affects both males and females equally, with symptoms often starting in childhood, adolescence, or young adulthood (ages 7 to 25 years). It is estimated that anywhere from 135,000 to 200,000 people in the United States (US) have narcolepsy.1

People with narcolepsy are often misdiagnosed with other conditions, such as psychiatric disorders or medical disorders, delaying proper diagnosis and treatment for years.

The main symptom of narcolepsy is excessive daytime sleepiness.2 Excessive daytime sleepiness is characterized by persistent sleepiness, regardless of nighttime sleep accrual, and is often described as a “sleep attack” where patients experience a sudden and overwhelming sense of sleepiness.1 In between sleep attacks, however, patients with narcolepsy experience normal levels of alertness.

Other symptoms of narcolepsy may include:

  • 1. Sudden loss of muscle tone
  • 2. Sleep paralysis
  • 3. Hallucinations

To treat narcolepsy, a doctor may prescribe stimulants to help keep you alert and awake throughout the day. A doctor may also suggest other medications, like antidepressants, to help manage the condition.

The Narcolepsy Clinical Study is evaluating an investigational drug (also known as the “study drug”) called SUVN-G3031 as a possible treatment for narcolepsy with cataplexy or narcolepsy without cataplexy, a sleep disorder that causes daytime drowsiness with or without muscle weakness.

References:

Frequently Asked Questions

What is the purpose of the Narcolepsy Clinical Study?

The Narcolepsy Clinical Study is evaluating an investigational drug (also known as the “study drug”) called SUVN-G3031 as a possible treatment for narcolepsy with cataplexy or narcolepsy without cataplexy, which means you have a sleep disorder that causes daytime drowsiness with or without muscle weakness. An investigational drug is one that has not been approved by the United States Food and Drug Administration.

The main purpose of this study is to learn how well the study drug works and how safe the study drug is compared with a placebo. A placebo is an inactive material that looks like the study drug but does not contain any active study drug. Researchers use a placebo to see if the study drug works better than taking nothing, and that the study drug is safe.

You will be in this study for up to 7 weeks, and you will need to come to the study center at least 5 times over this period.

The study is divided into 4 time periods: a screening period, a washout period, a treatment period, and a follow-up period. During each study period, you will have one or more visits with your study doctor at the center. For Visits 1, 2, and 3, you will stay overnight at the study clinic for a sleep study.

The study drug will be given at no cost to you, and you will not be charged for any study doctor visits, laboratory work, tests, or procedures that are needed for the study.

The following payments will be made to compensate you for your time and to reimburse you for transportation or parking payments related to visiting the study center:
You will receive minor compensation for the screening visit and the safety follow up visit and approximately $200 for each night spent in the sleep center (Visits 1, 2, and 3). You will be reimbursed after each completed study visit.

The research team will be able to explain more about what the Narcolepsy Clinical Study will involve, and it is up to you to decide if you want to take part. Participation in this study is voluntary. Whether or not you decide to participate in this study will not affect your current or future relationships with your doctors. If you decide to participate, you are free to withdraw at any time without affecting those relationships.

We match you to a study site within a close travel distance from your home. If we are not running the study in your area currently, with your permission, we will keep you in our database and reach out once a study in your area becomes available. If, at any time, you decide you no longer want your information stored, you can opt out and we will delete your details.

About the Narcolepsy Clinical Study

This study will take place in approximately 50 centers in the United States with about 114 to 171 adults with narcolepsy.

Participants will be in this study for up to 7 weeks, and you will need to come to the study center at least 5 times over this period.

The study is divided into 4 time periods: a screening period, a washout period, a treatment period, and a follow-up period. During each study period, you will have one or more visits with your study doctor at the center. For Visits 1, 2, and 3, you will stay overnight at the study clinic for a sleep study.

The study drug will be given at no cost to you, and you will not be charged for any study doctor visits, laboratory work, tests, or procedures that are needed for the study.

Participants will be reimbursed after each completed study visit.

Who can take part in the Narcolepsy Clinical Study?

To be eligible for this study, you must be:

  • 18 to 50 years of age
  • Diagnosed with narcolepsy with or without cataplexy
  • Interested in participating in a narcolepsy clinical research study

All study-related care is provided by Specialist Study Doctors.

The Narcolepsy Clinical Study is evaluating an investigational drug (also known as the “study drug”) called SUVN-G3031 as a possible treatment for narcolepsy with cataplexy or narcolepsy without cataplexy, a sleep disorder that causes daytime drowsiness with or without muscle weakness.